9. Patients may have measurable (according to Response Evaluation Criterion in Solid Tumors (RECIST v1.1) or not measurable disease Patients with only blastic bone lesions are not eligible; Patients with only pleural, cardiac or peritoneal effusion or meningeal carcinomatosis are not eligible;